Over a week ago
On The Fly
Welcome to "Fly Insider,"…
Show Hide Related Items >> <<
06/08/22 United Airlines announces nonstop service between San Francisco and Brisbane 06/06/22 United Airlines director buys $2.24M in common stock 05/18/22 United applies to launch nonstop service between Washington, D.C., Cape Town 05/17/22 United Airlines raises Q2 TRASM outlook to up 23%-25% from up 17% 05/31/22 Tela Bio secures up to $50M in debt financing from MidCap Financial 04/18/22 Tela Bio appoints D. Taylor Ocasio as general counsel 03/03/22 Tela Bio announces US launch of SiteGuard No Rinse Antimicrobial Solution 05/10/22 SoFi Technologies off lows after resumption, remains down 13% 05/10/22 SoFi Technologies trading resumes 05/10/22 SoFi Technologies to resume trading at 2:10 pm ET 05/10/22 SoFi Technologies CEO says 'off to a great start' standing up bank 06/08/22 Chewy director Star buys $5.0M in common stock 06/02/22 Chewy rises 20.1% 06/02/22 Chewy rises 15.2% 06/02/22 Chewy rises 10.3% 01/13/22 Aspen Aerogels CFO John Fairbanks to retire, Ricardo Rodriguez to succeed 01/11/22 Aptiv to acquire Wind River from TPG Capital for $4.3B in cash 05/19/22 American Electric releases 2022 Corporate Sustainability Report 03/30/22 American Electric names Sandy Nessing as VP, chief sustainability officer 01/21/22 Iris Energy executes 600MW connection agreement with AEP Texas 12/30/21 American Electric completes sale of Racine hydroelectric plant 05/11/22 Airbnb introduces 'biggest change in decade,' all-new-design 05/03/22 Airbnb reports Q1 Gross Booking Value up 67% to $17.2B 04/11/22 Airbnb director Belinda Johnson sells $3.26M in common stock 03/18/22 Vacasa CEO: We're strong partners with Airbnb, Booking Holdings 05/27/22 Agilent, APC announce liquid chromatography collaboration agreement 05/10/22 Agilent reports expanded CE-IVD mark in Europe for companion diagnostic 04/05/22 Agilent expands CE-IVD marking in EU for PD-L1 IHC 28-8 pharmDx 02/28/22 Singular Genomics partners with Agilent for NGS Target Enrichment products 05/31/22 Lake Street Tela Bio initiated with a Buy at Lake Street 05/06/22 Wolfe Research United Airlines upgraded to Peer Perform from Underperform at Wolfe Research 04/25/22 Citi United Airlines price target raised to $71 from $58 at Citi 04/22/22 MKM Partners United Airlines price target raised to $59 from $53 at MKM Partners 04/22/22 Morgan Stanley United Airlines price target raised to $67 from $62 at Morgan Stanley 06/03/22 Wells Fargo Chewy price target lowered to $55 from $65 at Wells Fargo 06/02/22 Citi Chewy price target lowered to $29 from $45 at Citi 06/02/22 Baird Chewy price target lowered to $45 from $60 at Baird 06/02/22 RBC Capital Chewy price target lowered to $59 from $73 at RBC Capital 05/17/22 Mizuho SoFi Technologies price target lowered to $9 from $14 at Mizuho 05/16/22 Piper Sandler Piper upgrades SoFi to buy ahead of 'significant' earnings ramp 05/16/22 Piper Sandler SoFi Technologies upgraded to Overweight from Neutral at Piper Sandler 05/12/22 Citi SoFi Technologies price target lowered to $11 from $17 at Citi 06/03/22 Cowen Agilent premium valuation remains warranted, says Cowen 06/02/22 KeyBanc Agilent price target lowered to $155 from $195 at KeyBanc 05/25/22 Baird Agilent price target raised to $161 from $155 at Baird 05/16/22 Citi Citi opens 'positive catalyst watch' on Agilent into earnings 04/25/22 Credit Suisse American Electric initiated with an Outperform at Credit Suisse 03/29/22 Mizuho American Electric price target raised to $104 from $94 at Mizuho 03/14/22 Seaport Global American Electric downgraded to Neutral after strategic shift at Seaport Global 03/14/22 Seaport Global American Electric downgraded to Neutral from Buy at Seaport Global 06/01/22 Goldman Sachs Aptiv price target lowered to $135 from $150 at Goldman Sachs 06/01/22 Morgan Stanley Aptiv price target lowered to $155 from $170 at Morgan Stanley 05/09/22 Deutsche Bank Aptiv price target lowered to $137 from $140 at Deutsche Bank 05/06/22 Cowen Aptiv price target lowered to $144 from $150 at Cowen 06/09/22 Goldman Sachs Airbnb price target lowered to $95 from $150 at Goldman Sachs 06/03/22 Truist Airbnb price target lowered to $160 from $190 at Truist 05/12/22 Citi Airbnb share 'dislocation' brings buying opportunity, says Citi 05/11/22 Truist Airbnb's new features should contribute to bookings growth, says Truist 04/20/22 United Airlines reports Q1 adjusted EPS ($4.24), consensus ($4.21) 04/20/22 Notable companies reporting after market close 03/15/22 United Airlines sees Q1 capacity down approximately 19% 01/19/22 United Airlines sees FY22 capacity down vs 2019 05/10/22 Tela Bio reaffirms FY22 revenue $40M-$45M, consensus $42.61M 05/10/22 Tela Bio reports Q1 EPS (75c), consensus (56c) 03/21/22 Tela Bio sees FY22 revenue 40M-$45M, consensus $43.45M 03/21/22 Tela Bio reports Q EPS (59c), consensus (55c) 05/10/22 SoFi Technologies sees FY22 adjusted revenue $1.505B-$1.51B, consensus $1.46B 05/10/22 SoFi Technologies sees Q2 adjusted net revenue $330M-$340M, consensus $343.9M 05/10/22 SoFi Technologies reports Q1 EPS (14c), consensus (14c) 05/10/22 SoFi Technologies sees FY22 adjusted revenue $1.51B, Bloomberg says 06/01/22 Chewy reports Q1 EPS 4c, consensus (14c) 06/01/22 Notable companies reporting after market close 03/29/22 Chewy sees FY22 revenue $10.2B-$10.4B, consensus $10.61B 03/29/22 Chewy sees Q1 revenue $2.40B-$2.43B, consensus $2.51B 05/05/22 Aptiv backs FY22 adjusted EPS view $3.90-$4.80, consensus $3.88 05/05/22 Aptiv reports Q1 adjusted EPS 63, consensus 61c 02/03/22 Aptiv sees FY22 adjusted EPS $3.90-$4.80, consensus $4.56 02/03/22 Aptiv reports Q4 adjusted EPS 56c, consensus 55c 04/28/22 American Electric backs FY22 operating EPS view $4.87-$5.07, consensus $4.99 04/28/22 American Electric reports Q1 EPS $1.22, consensus $1.20 02/24/22 American Electric sees FY22 EPS $4.87-$5.07, consensus $4.96 02/24/22 American Electric reports Q4 EPS 98c, consensus 93c 05/03/22 Airbnb sees Q2 revenue $2.03B-$2.13B, consensus $1.97B 05/03/22 Airbnb reports Q1 EPS (3c), consensus (29c) 05/03/22 Notable companies reporting after market close 02/15/22 Airbnb sees Q1 revenue $1.41B-$1.48B, consensus $1.24B 05/24/22 Agilent raises FY22 EPS view to $4.86-$4.93, consensus $4.60 05/24/22 Agilent sees Q3 EPS $1.20-$1.22, consensus $1.12 05/24/22 Agilent reports Q2 EPS $1.13, consensus $1.06 02/22/22 Agilent raises FY22 EPS view to $4.80-$4.90, consensus $4.27
Conference/Events
2022 ASCO Annual Meeting…
2022 ASCO Annual Meeting to be held in Chicago on June 3-7.
Show Hide Related Items >> <<
05/17/22 VBL expects cash to be sufficient for at least a year beyond OVAL results 04/26/22 VBL Therapeutics receives FDA Fast Track designation for ofra-vec 03/31/22 VBL Therapeutics to host KOL seminar on ovarian cancer 03/08/22 VBL announces completion of enrollment in OVAL Phase 3 trial of ofra-vec 06/06/22 Seagen, Genmab present data from tisotumab vedotin clinical development program 06/03/22 Seagen says trial data show Adcetris, AVE-PC combo was well tolerated 05/23/22 Seagen gives topline results of Phase 2 trial of tucatinib/trastuzumab combo 05/16/22 Seagen CEO Clay Siegall resigns, Roger Dansey to continue as interim CEO RTX Raytheon Technologies 06/02/22 NASA selects Axiom, Collins Aerospace for space suit contract 05/27/22 Raytheon Technologies awarded $624.6M Army contract modification 05/26/22 Raytheon Technologies awarded $408.4M Navy contract modification 05/24/22 Raytheon Technologies awarded $217.12M Navy contract 06/01/22 Repare Therapeutics enters global license agreement with Rohce on RP-3500 05/31/22 FDA approves Roche's Evrysdi for use in babies under two months with SMA 05/26/22 Roche to present data demonstrating clinical benefit of Genentech's Glofitamab 05/25/22 Roche's Polivy combination approved by EC for previously untreated DLBCL 06/06/22 Pfizer to invest $120M at Michigan facility for Paxlovid production 06/05/22 Pfizer announces overall survival results from Phase 3 PALOMA-2 Trial of IBRANCE 06/02/22 Pfizer, Myovant Sciences announce FDA approval of sNDA for MYFEMBREE 06/01/22 Pfizer plans to exit ownership interest in Haleon 06/05/22 Puma presents results from biliary tract cohort of Phase 2 SUMMIT basket trial 05/26/22 Puma Biotechnology to present two abstracts on neratinib at ASCO Meeting 02/15/22 Coherus Biosciences announces Paul Reider as chief commercial officer 01/12/22 Puma Biotechnology's NERLYNX included in NCCN guidelines for breast cancer 05/04/22 Oncolytics and SOLTI's pelareorep shows breast cancer prognosis efficacy in stud 04/14/22 Oncolytics' pelareorep shows anti-cancer potential in publication 04/08/22 Oncolytics reports 'positive' long-term survival data from ReoGlio trial 03/31/22 Oncolytics provides update on phase 1/2 GOBLET study 06/03/22 Invitae falls -14.4% 06/03/22 Invitae falls -11.5% 06/03/22 Invitae falls -6.9% 05/26/22 Invitae to present eight studies at ASCO 06/06/22 Novartis says Tafinlar+Mekinist had 'unprecedented efficacy' in pediatric study 06/01/22 Knight Therapeutics assumes commercial activities for Exelon in Colombia 05/28/22 FDA approves Novartis' Kymriah CAR-T cell therapy for r/r follicular lymphoma 05/23/22 Insmed names Drayton Wise as Chief Commercial Officer 06/03/22 NeoGenomics receives CAP certfication in Suzhou China laboratory 05/16/22 NeoGenomics appoints Lynn Terault as interim CEO 05/16/22 NeoGenomics Chief Strategy and Corporate Development Officer to step down 05/16/22 NeoGenomics appoints Lynn Tetrault interim CEO 06/06/22 Molecular Templates presents on PD-L1, HER2 programs at ASCO 05/12/22 Molecular Templates sees cash, investments funding operations to end of 2023 04/12/22 Molecular Templates reviews six poster presentations at AACR 2022 meeting 04/08/22 Molecular Templates to host webinar on immuno-oncology for solid tumors GLSI Greenwich LifeSciences 05/23/22 Greenwich LifeSciences to resume stock repurchase plan 05/23/22 Greenwich LifeSciences provides updates on Phase 3 clinical trial 04/21/22 Greenwich LifeSciences CEO buys $100K in common stock 02/01/22 Greenwich LifeSciences provides update on Phase III trial of Flamingo-01 05/09/22 FibroGen announces upcoming milestones 04/20/22 FibroGen announces completion of patient enrollment for ZEPHYRUS-1 12/20/21 FibroGen exercises exclusive license option for HiFiBiO's CCR8 program 05/26/22 Exelixis announces results from multiple cohorts of COSMIC-021 trial 04/14/22 Exelixis starts 1st-in-human trial evaluating XL114 as a monotherapy for NHL 04/12/22 Vera Therapeutics appoints Morrissey as chairman of its board of directors 03/14/22 Exelixis does not intend to submit supplemental NDA to FDA for cabometyx 05/05/22 AstraZeneca's Enhertu approved in U.S. in HER2-positive breast cancer 04/26/22 AstraZeneca's Enhertu granted breakthrough therapy designation in U.S. 03/07/22 Centessa expands management team with two new appointments 02/21/22 AstraZeneca reports 'positive high-level results' from DESTINY-Breast04 trial $21.53 / +2.405 (+12.58%)
05/24/22 Castle Biosciences announces results from TissueCypher Barrett's Esophagus study 05/19/22 Castle Biosciences' DecisionDx-SCC shows risk-stratification efficacy in study 05/10/22 Castle Biosciences teams with The Sun Bus to provide free skin cancer tests 04/27/22 Castle Biosciences announces publication of TissueCypher study CBIO Catalyst Biosciences 05/23/22 Catalyst Biosciences sells complement portfolio for $60M 03/15/22 Catalyst Biosciences regains full rights to CB 2782-PEG 02/17/22 Catalyst engages Perella Weinberg to assist in exploring strategic alternatives 01/25/22 Catalyst Biosciences receives RPDD for CB 4332 for treatment of CFID 06/02/22 Cardinal Health adds new distribution center in the Columbus Ohio area 05/11/22 Cardinal Health awarded $2.25B Defense Department contract modification 05/10/22 Cardinal Health raises quarterly dividend to 49.57c per share 05/03/22 Distributors agree to $518M opioid settlement With Washington state 06/03/22 Biodesix announces research agreement with top U.S. cancer center 04/11/22 Biodesix director Strobeck buys $1M in company shares 03/29/22 Biodesix announces publication of data from GeneStrat NGS test studies 03/07/22 Biodesix announces stock buyback for up to $50M with Lincoln Park Capital 05/26/22 Aura Biosciences announces publication of preclinical data on AU-011 at ASCO 05/03/22 Aura Biosciences presents preclinical data on AU-011's anti-tumor activity 03/21/22 Aura Biosciences: AU-011gets EU orphan drug designation for uveal melanoma 05/09/22 Arvinas, GNS Healthcare announce neuroscience drug discovery collaboration 05/05/22 Arvinas announces anticipated milestones and expectations 02/17/22 Arvinas announces Phase 1, interim Phase 2 data for bavdegalutamide 02/17/22 Arvinas announces Phase 1, interim Phase 2 data for bavdegalutamide 05/27/22 Sarissa condemns 'poor' corporate governance at Alkermes 04/27/22 Alkermes jumps 11% to $30.23 following Q1 beat 04/19/22 Alkermes begins arbitration regarding two license agreements with Janssen 02/17/22 Alkermes presents new data on nemvaleukin alfa monotherapy 05/09/22 Adaptimmune names Joanna Brewer as chief scientific officer 05/09/22 Adaptimmune sees cash, equivalents funding operations into early 2024 05/04/22 Adaptimmune appoints Joanna Brewer as CSO 04/08/22 Adaptimmune presents MAGE-A4 expression data from screening protocol $15.92 / +3.295 (+26.10%)
06/03/22 Arcellx reports 'positive' clinical data from Phase 1 CART-ddBCMA study 05/23/22 Arcellx appoints Michelle Gilson as CFO 05/10/22 Arcellx doses first patient in ACLX-001 Phase 1 clinical study of ARC-SparX 05/10/22 Arcellx Inc trading resumes 06/06/22 Adicet Bio outlines data from ADI-001 study at ASCO meeting 05/26/22 Adicet Bio's ADI-001 shows 67% response rate for NHL in Phase 1 trial 04/19/22 Adicet Bio gets FDA fast track designation for lead candidate ADI-001 06/03/22 Janssen says Imbruvica combo reduced lymphoma death by 25% in study 06/01/22 AbbVie: Phase 3 SELECT-AXIS 2 program met primary endpoint 05/27/22 AbbVie announces results from three trials evaluating upadacitinib published 05/25/22 West Virginia reaches $161M opioid settlement with Teva, AbbVie 05/27/22 Agilent, APC announce liquid chromatography collaboration agreement 05/10/22 Agilent reports expanded CE-IVD mark in Europe for companion diagnostic 04/05/22 Agilent expands CE-IVD marking in EU for PD-L1 IHC 28-8 pharmDx 02/28/22 Singular Genomics partners with Agilent for NGS Target Enrichment products 06/03/22 Cowen Agilent premium valuation remains warranted, says Cowen 06/02/22 KeyBanc Agilent price target lowered to $155 from $195 at KeyBanc 05/25/22 Baird Agilent price target raised to $161 from $155 at Baird 05/16/22 Citi Citi opens 'positive catalyst watch' on Agilent into earnings 04/28/22 Mizuho Alkermes price target raised to $36 from $35 at Mizuho 04/28/22 H.C. Wainwright Alkermes price target raised to $32 from $30 at H.C. Wainwright 04/27/22 Stifel Alkermes price target raised to $27 from $24 at Stifel 04/20/22 Goldman Sachs Alkermes initiated with a Buy at Goldman Sachs 05/12/22 Canaccord Biodesix price target lowered to $7 from $10 at Canaccord 04/20/22 Cowen Biodesix initiated with an Outperform at Cowen 04/18/22 BTIG Biodesix price target lowered to $10 from $17 at BTIG 03/15/22 Canaccord Biodesix price target lowered to $10 from $18 at Canaccord $21.53 / +2.405 (+12.58%)
05/19/22 Baird Baird says final LCD for test 'incrementally positive' for Castle Biosciences 05/10/22 Canaccord Castle Biosciences price target lowered to $65 from $80 at Canaccord 05/10/22 Baird Castle Biosciences price target lowered to $44 from $50 at Baird 05/09/22 BTIG Castle Biosciences transferred with a Buy at BTIG 05/23/22 SVB Securities AbbVie initiated with an Underperform at SVB Leerink 05/13/22 Piper Sandler Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler 05/06/22 Daiwa AbbVie downgraded to Neutral from Outperform at Daiwa 05/03/22 Morgan Stanley Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 03/17/22 JMP Securities Adicet Bio price target lowered to $21 from $30 at JMP Securities 03/08/22 Truist Adicet Bio initiated with a Buy at Truist 03/04/22 Jefferies Adicet Bio initiated with a Buy at Jefferies $15.92 / +3.295 (+26.10%)
03/02/22 Barclays Arcellx initiated with an Overweight at Barclays 03/01/22 SVB Securities Arcellx initiated with an Outperform at SVB Leerink 03/01/22 BofA Arcellx initiated with a Buy at BofA 03/01/22 BofA Arcellx initiated with a Buy at BofA 11/11/21 Roth Capital Roth says Adaptimmune synovial sarcoma trial hitting goal appears 'a certainty' 06/03/22 Oppenheimer Turning Point Therapeutics downgraded to Perform from Outperform at Oppenheimer 05/31/22 Evercore ISI Enanta upgraded to In Line from Underperform at Evercore ISI 05/25/22 Piper Sandler Piper Sandler says Ventyx Biosciences' VTX002 could produce superior efficacy 05/23/22 Piper Sandler Biohaven price target lowered to $149 from $170 at Piper Sandler 05/06/22 H.C. Wainwright Puma Biotechnology price target lowered to $12 from $14 at H.C. Wainwright 09/28/21 Fly Intel: Top five analyst upgrades 09/28/21 Citi Puma Biotechnology upgraded to Buy after 40% selloff at Citi 09/27/21 Citi Puma Biotechnology upgraded to Buy from Neutral at Citi 01/27/22 Canaccord Oncolytics price target lowered to $6 from $7 at Canaccord 06/02/22 Piper Sandler Invitae initiated with an Underweight at Piper Sandler 05/04/22 Raymond James Invitae price target lowered to $8.50 from $10.50 at Raymond James 02/28/22 Raymond James Invitae price target lowered to $15 from $36 at Raymond James 11/09/21 Wells Fargo Invitae price target lowered to $25 from $35 at Wells Fargo 05/13/22 Piper Sandler Point Biopharma price target lowered to $14 from $17 at Piper Sandler 05/13/22 Jefferies Roche downgraded to Hold from Buy at Jefferies 05/09/22 Wolfe Research Novartis downgraded to Peer Perform from Outperform at Wolfe Research 06/02/22 Piper Sandler NeoGenomics initiated with an Overweight at Piper Sandler 03/29/22 Cowen NeoGenomics price target lowered to $24 from $42 at Cowen 03/29/22 BTIG NeoGenomics price target lowered to $28 from $35 at BTIG 03/29/22 SVB Securities NeoGenomics price target lowered to $20 from $45 at SVB Leerink 05/27/22 BofA Molecular Templates downgraded to Underperform from Buy at BofA 05/13/22 Stifel Molecular Templates price target lowered to $9 from $11 at Stifel 03/30/22 Barclays Molecular Templates price target lowered to $4.50 from $8 at Barclays 04/28/22 Chardan VBL Therapeutics initiated with a Buy at Chardan 08/30/21 Roth Capital Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes 06/15/21 Roth Capital Roth does not see material change to VBL readout timelines 10/27/21 SVB Securities Seagen price target raised to $200 from $190 at SVB Leerink GLSI Greenwich LifeSciences 09/01/21 H.C. Wainwright Greenwich LifeSciences initiated with a Buy at H.C. Wainwright RTX Raytheon Technologies 04/27/22 Argus Raytheon Technologies price target raised to $112 from $100 at Argus 04/27/22 Cowen Raytheon Technologies price target raised to $120 from $115 at Cowen 04/08/22 RBC Capital Raytheon Technologies initiated with an Outperform at RBC Capital 03/29/22 Jefferies Northrop among biggest beneficiaries of DoD budget request, says Jefferies 04/08/22 Roth Capital Bicycle reported 'very strong' side-effect profile, says Roth Capital 04/08/22 Cantor Fitzgerald Bicycle Therapeutics' BT8009 abstract 'very positive,' says Cantor Fitzgerald 02/24/22 Piper Sandler Seagen's tisotumab vedotin shows 'modest signal of activity,' says Piper Sandler 02/16/22 JMP Securities Seagen price target lowered to $142 from $201 at JMP Securities 06/02/22 Piper Sandler Piper ups Repare Therapeutics target after 'great deal' with Roche 05/19/22 Credit Suisse Roche price target lowered to CHF 350 from CHF 370 at Credit Suisse 05/12/22 Morgan Stanley Roche price target lowered to CHF 370 from CHF 395 at Morgan Stanley 05/19/22 Piper Sandler Exelixis sold off on Cabometyx patent trial comments, says Piper Sandler 05/19/22 Truist Exelixis should be bought on dip caused by '776 patent worries, says Truist 05/12/22 Jefferies Exelixis could approach $26-$28 if it settles or wins MSN trial, says Jefferies 03/14/22 Piper Sandler Exelixis price target lowered to $30 from $34 at Piper Sandler 09/22/21 Fly Intel: Top five analyst downgrades 09/22/21 Goldman Sachs FibroGen downgraded to Sell from Neutral at Goldman Sachs 08/20/21 Raymond James FibroGen upgraded to Market Perform from Underperform at Raymond James 08/20/21 Raymond James FibroGen upgraded to Market Perform from Underperform at Raymond James 05/26/22 Barclays Cardinal Health downgraded to Equal Weight from Overweight at Barclays 05/18/22 Evercore ISI Evercore upgrades Cardinal Health to Outperform on undervalued Medical segment 05/18/22 Evercore ISI Cardinal Health upgraded to Outperform from In Line at Evercore ISI 04/12/22 Morgan Stanley McKesson price target raised to $370 from $292 at Morgan Stanley CBIO Catalyst Biosciences 05/23/22 Piper Sandler Piper Sandler remains bullish on Catalyst after sale of complement portfolio 03/31/22 Piper Sandler Piper says 'stick it out' with Catalyst Biosciences exploring options 11/12/21 JonesTrading Catalyst Biosciences downgraded to Hold from Buy at JonesTrading 11/12/21 Piper Sandler Catalyst Biosciences price target lowered to $4 from $16 at Piper Sandler 05/23/22 Piper Sandler Arvinas price target lowered to $76 from $116 at Piper Sandler 05/09/22 Wedbush Wedbush downgrades Arvinas to Neutral, cuts price target to $43 05/09/22 Wedbush Arvinas downgraded to Neutral from Outperform at Wedbush 05/06/22 Cantor Fitzgerald Arvinas assumed with an Overweight at Cantor Fitzgerald 11/23/21 SVB Securities Aura Biosciences initiated with an Outperform at SVB Leerink 11/23/21 BTIG Aura Biosciences initiated with a Buy at BTIG 11/23/21 Evercore ISI Evercore starts Aura Biosciences at Outperform with $35 price target 11/23/21 Cowen Aura Biosciences initiated with an Outperform at Cowen 05/17/22 VBL Therapeutics reports Q1 EPS (13c), consensus (11c) 03/23/22 VBL Therapeutics reports FY21 EPS (45c), consensus (41c) 04/28/22 Seagen sees FY22 total revenue $1.665B-$1.745B, consensus $1.78B 04/28/22 Seagen reports Q1 EPS (74c), consensus ($1.00) 02/10/22 Seagen sees FY22 total revenue $1.67B-$1.75B, consensus $2.16B 02/09/22 Seagen reports Q4 EPS (95c), consensus (83c) RTX Raytheon Technologies 04/26/22 Raytheon Technologies backs FY22 adjusted EPS view $4.60-$4.80, consensus $4.79 04/26/22 Raytheon Technologies reports Q1 adjusted EPS $1.15, consensus $1.01 04/25/22 Notable companies reporting before tomorrow's open 04/25/22 Roche reports Q1 group sales CHF 16.445B vs. CHF 14.93B last year 02/03/22 Roche sees FY22 core earnings growing in low- to mid-single digit range 02/03/22 Roche reports 2021 core EPS CHF 19.81 vs CHF 19.16 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open 05/05/22 Puma Biotechnology reports Q1 EPS (1c), consensus (17c) 03/03/22 Puma Biotechnology reports Q4 EPS 21c, consensus (9c) 05/05/22 Oncolytics reports Q1 EPS 12c, consensus (11c) 03/03/22 Oncolytics reports Q4 EPS (14c), consensus (10c) 05/03/22 Invitae reports Q1 non-GAAP EPS 78c, consensus (76c) 02/24/22 Invitae sees 2022 revenue $640M, consensus $638.69M 02/24/22 Invitae reports Q4 non-GAAP EPS (81c), consensus (73c) 04/26/22 Novartis sees 2022 core operating income to grow mid single digit 04/26/22 Novartis reports Q1 core EPS $1.46, consensus $1.46 02/02/22 Novartis sees 2022 sales, core operating income up mid single digit 02/02/22 Novartis reports Q4 core EPS $1.40 vs. $1.34 last year 04/27/22 NeoGenomics reports Q1 adjusted EPS (20c), consensus (23c) 04/26/22 Notable companies reporting before tomorrow's open 03/28/22 NeoGenomics now sees Q1 revenue below $118M-$120M range, consensus $119.16M 05/13/22 Molecular Templates reports Q1 EPS (38c), consensus (47c) 03/28/22 Molecular Templates reports Q4 EPS (18c), consensus (40c) 05/09/22 FibroGen reports Q1 EPS (68c), consensus (83c) 02/28/22 FibroGen reports Q EPS ($1.45), consensus (66c) 05/10/22 Exelixis sees FY22 revenue $1.525B-$1.625B, consensus $1.64B 05/10/22 Exelixis reports Q1 adjusted EPS 26c, consensus 14c 02/17/22 Exelixis reports Q4 adjusted EPS 35c, consensus 6c 01/09/22 Exelixis sees preliminary Q4 net product revenue $300M $21.53 / +2.405 (+12.58%)
05/09/22 Castle Biosciences raises FY22 revenue view to $118M-$123M from $115M-$120M 05/09/22 Castle Biosciences reports Q1 EPS (97c), consensus (71c) 02/28/22 Castle Biosciences sees FY22 revenue $115M-$120M, consensus $113.54M 02/28/22 Castle Biosciences reports Q4 EPS (25c), consensus (47c) CBIO Catalyst Biosciences 05/09/22 Catalyst Biosciences reports Q1 EPS (46c), consensus (44c) 03/31/22 Catalyst Biosciences reports Q4 EPS (65c), consensus (59c) 05/05/22 Cardinal Health narrows FY21 EPS view to $5.15-$5.25 from $5.15-$5.50 05/05/22 Cardinal Health reports Q3 EPS $1.45, consensus $1.52 02/03/22 Cardinal Health cuts FY22 EPS view to $5.15-$5.50 from $5.60-$5.90 02/03/22 Cardinal Health reports Q2 EPS $1.27, consensus $1.23 05/11/22 Biodesix still sees 2022 revenue $37.5M-$39.5M, consensus $38.41M 05/11/22 Biodesix reports Q1 EPS (50c), consensus (40c) 03/14/22 Biodesix sees FY22 revenue $37.5M-$39.5M, consensus $35.5M 03/14/22 Biodesix reports Q4 EPS (49c), consensus (49c) 03/23/22 Aura Biosciences reports FY21 EPS ($8.95), consensus ($4.41) 05/05/22 Arvinas reports Q1 EPS ($1.20), consensus (89c) 02/28/22 Arvinas reports Q4 EPS ($1.00), consensus (79c) 04/27/22 Alkermes reiterates 2022 financial expectations given in February 04/27/22 Alkermes reports Q1 EPS 12c, consensus 1c 02/16/22 Alkermes updates long-term profitability targets for Invega royalty removal 02/16/22 Alkermes sees FY22 adjusted EPS (18c)-0c, consensus 35c 05/09/22 Adaptimmune reports Q1 EPS (5c), consensus (22c) 03/14/22 Adaptimmune reports Q4 EPS (4c), consensus 14c $15.92 / +3.295 (+26.10%)
05/12/22 Arcellx reports Q1 EPS ($1.56), consensus (64c) 03/24/22 Arcellx reports Q4 EPS ($39.85) vs. ($28.27) a year ago 06/06/22 Notable companies reporting after market close 05/12/22 Adicet Bio reports Q1 EPS (12c), consensus (18c) 03/15/22 Adicet Bio reports Q4 EPS (47c), consensus (42c) 04/29/22 AbbVie sees FY22 revenue $59.4B, consensus $60.22B 04/29/22 AbbVie sees Q2 adjusted EPS $3.38-$3.42, consensus $3.50 04/29/22 AbbVie cuts FY22 adjusted EPS view to $13.92-$14.12 from $14.00-$14.20 04/29/22 AbbVie reports Q1 adjusted EPS $3.16, consensus $3.14 05/24/22 Agilent raises FY22 EPS view to $4.86-$4.93, consensus $4.60 05/24/22 Agilent sees Q3 EPS $1.20-$1.22, consensus $1.12 05/24/22 Agilent reports Q2 EPS $1.13, consensus $1.06 02/22/22 Agilent raises FY22 EPS view to $4.80-$4.90, consensus $4.27
Conference/Events
2022 ASCO Annual Meeting…
2022 ASCO Annual Meeting to be held in Chicago on June 3-7.
Show Hide Related Items >> <<
05/17/22 VBL expects cash to be sufficient for at least a year beyond OVAL results 04/26/22 VBL Therapeutics receives FDA Fast Track designation for ofra-vec 03/31/22 VBL Therapeutics to host KOL seminar on ovarian cancer 03/08/22 VBL announces completion of enrollment in OVAL Phase 3 trial of ofra-vec 06/03/22 Seagen says trial data show Adcetris, AVE-PC combo was well tolerated 05/23/22 Seagen gives topline results of Phase 2 trial of tucatinib/trastuzumab combo 05/16/22 Seagen CEO Clay Siegall resigns, Roger Dansey to continue as interim CEO 05/09/22 Seagen CEO Clay Siegall takes leave of absence, Roger Dansey named interim CEO RTX Raytheon Technologies 06/02/22 NASA selects Axiom, Collins Aerospace for space suit contract 05/27/22 Raytheon Technologies awarded $624.6M Army contract modification 05/26/22 Raytheon Technologies awarded $408.4M Navy contract modification 05/24/22 Raytheon Technologies awarded $217.12M Navy contract 06/01/22 Repare Therapeutics enters global license agreement with Rohce on RP-3500 05/31/22 FDA approves Roche's Evrysdi for use in babies under two months with SMA 05/26/22 Roche to present data demonstrating clinical benefit of Genentech's Glofitamab 05/25/22 Roche's Polivy combination approved by EC for previously untreated DLBCL 06/05/22 Pfizer announces overall survival results from Phase 3 PALOMA-2 Trial of IBRANCE 06/02/22 Pfizer, Myovant Sciences announce FDA approval of sNDA for MYFEMBREE 06/01/22 Pfizer plans to exit ownership interest in Haleon 06/01/22 GlaxoSmithKline provides update on demerger of consumer heathcare business 06/05/22 Puma presents results from biliary tract cohort of Phase 2 SUMMIT basket trial 05/26/22 Puma Biotechnology to present two abstracts on neratinib at ASCO Meeting 02/15/22 Coherus Biosciences announces Paul Reider as chief commercial officer 01/12/22 Puma Biotechnology's NERLYNX included in NCCN guidelines for breast cancer 05/04/22 Oncolytics and SOLTI's pelareorep shows breast cancer prognosis efficacy in stud 04/14/22 Oncolytics' pelareorep shows anti-cancer potential in publication 04/08/22 Oncolytics reports 'positive' long-term survival data from ReoGlio trial 03/31/22 Oncolytics provides update on phase 1/2 GOBLET study 06/03/22 Invitae falls -14.4% 06/03/22 Invitae falls -11.5% 06/03/22 Invitae falls -6.9% 05/26/22 Invitae to present eight studies at ASCO 06/06/22 Novartis says Tafinlar+Mekinist had 'unprecedented efficacy' in pediatric study 06/01/22 Knight Therapeutics assumes commercial activities for Exelon in Colombia 05/28/22 FDA approves Novartis' Kymriah CAR-T cell therapy for r/r follicular lymphoma 05/23/22 Insmed names Drayton Wise as Chief Commercial Officer 06/03/22 NeoGenomics receives CAP certfication in Suzhou China laboratory 05/16/22 NeoGenomics appoints Lynn Terault as interim CEO 05/16/22 NeoGenomics Chief Strategy and Corporate Development Officer to step down 05/16/22 NeoGenomics appoints Lynn Tetrault interim CEO 06/06/22 Molecular Templates presents on PD-L1, HER2 programs at ASCO 05/12/22 Molecular Templates sees cash, investments funding operations to end of 2023 04/12/22 Molecular Templates reviews six poster presentations at AACR 2022 meeting 04/08/22 Molecular Templates to host webinar on immuno-oncology for solid tumors GLSI Greenwich LifeSciences 05/23/22 Greenwich LifeSciences to resume stock repurchase plan 05/23/22 Greenwich LifeSciences provides updates on Phase 3 clinical trial 04/21/22 Greenwich LifeSciences CEO buys $100K in common stock 02/01/22 Greenwich LifeSciences provides update on Phase III trial of Flamingo-01 05/09/22 FibroGen announces upcoming milestones 04/20/22 FibroGen announces completion of patient enrollment for ZEPHYRUS-1 12/20/21 FibroGen exercises exclusive license option for HiFiBiO's CCR8 program 05/26/22 Exelixis announces results from multiple cohorts of COSMIC-021 trial 04/14/22 Exelixis starts 1st-in-human trial evaluating XL114 as a monotherapy for NHL 04/12/22 Vera Therapeutics appoints Morrissey as chairman of its board of directors 03/14/22 Exelixis does not intend to submit supplemental NDA to FDA for cabometyx 05/05/22 AstraZeneca's Enhertu approved in U.S. in HER2-positive breast cancer 04/26/22 AstraZeneca's Enhertu granted breakthrough therapy designation in U.S. 03/07/22 Centessa expands management team with two new appointments 02/21/22 AstraZeneca reports 'positive high-level results' from DESTINY-Breast04 trial 05/24/22 Castle Biosciences announces results from TissueCypher Barrett's Esophagus study 05/19/22 Castle Biosciences' DecisionDx-SCC shows risk-stratification efficacy in study 05/10/22 Castle Biosciences teams with The Sun Bus to provide free skin cancer tests 04/27/22 Castle Biosciences announces publication of TissueCypher study CBIO Catalyst Biosciences 05/23/22 Catalyst Biosciences sells complement portfolio for $60M 03/15/22 Catalyst Biosciences regains full rights to CB 2782-PEG 02/17/22 Catalyst engages Perella Weinberg to assist in exploring strategic alternatives 01/25/22 Catalyst Biosciences receives RPDD for CB 4332 for treatment of CFID 06/02/22 Cardinal Health adds new distribution center in the Columbus Ohio area 05/11/22 Cardinal Health awarded $2.25B Defense Department contract modification 05/10/22 Cardinal Health raises quarterly dividend to 49.57c per share 05/03/22 Distributors agree to $518M opioid settlement With Washington state 06/03/22 Biodesix announces research agreement with top U.S. cancer center 04/11/22 Biodesix director Strobeck buys $1M in company shares 03/29/22 Biodesix announces publication of data from GeneStrat NGS test studies 03/07/22 Biodesix announces stock buyback for up to $50M with Lincoln Park Capital 05/26/22 Aura Biosciences announces publication of preclinical data on AU-011 at ASCO 05/03/22 Aura Biosciences presents preclinical data on AU-011's anti-tumor activity 03/21/22 Aura Biosciences: AU-011gets EU orphan drug designation for uveal melanoma 05/09/22 Arvinas, GNS Healthcare announce neuroscience drug discovery collaboration 05/05/22 Arvinas announces anticipated milestones and expectations 02/17/22 Arvinas announces Phase 1, interim Phase 2 data for bavdegalutamide 02/17/22 Arvinas announces Phase 1, interim Phase 2 data for bavdegalutamide 05/27/22 Sarissa condemns 'poor' corporate governance at Alkermes 04/27/22 Alkermes jumps 11% to $30.23 following Q1 beat 04/19/22 Alkermes begins arbitration regarding two license agreements with Janssen 02/17/22 Alkermes presents new data on nemvaleukin alfa monotherapy 05/09/22 Adaptimmune names Joanna Brewer as chief scientific officer 05/09/22 Adaptimmune sees cash, equivalents funding operations into early 2024 05/04/22 Adaptimmune appoints Joanna Brewer as CSO 04/08/22 Adaptimmune presents MAGE-A4 expression data from screening protocol 06/03/22 Arcellx reports 'positive' clinical data from Phase 1 CART-ddBCMA study 05/23/22 Arcellx appoints Michelle Gilson as CFO 05/10/22 Arcellx doses first patient in ACLX-001 Phase 1 clinical study of ARC-SparX 05/10/22 Arcellx Inc trading resumes 06/06/22 Adicet Bio outlines data from ADI-001 study at ASCO meeting 05/26/22 Adicet Bio's ADI-001 shows 67% response rate for NHL in Phase 1 trial 04/19/22 Adicet Bio gets FDA fast track designation for lead candidate ADI-001 12/06/21 Adicet Bio trading resumes 06/03/22 Janssen says Imbruvica combo reduced lymphoma death by 25% in study 06/01/22 AbbVie: Phase 3 SELECT-AXIS 2 program met primary endpoint 05/27/22 AbbVie announces results from three trials evaluating upadacitinib published 05/25/22 West Virginia reaches $161M opioid settlement with Teva, AbbVie 05/27/22 Agilent, APC announce liquid chromatography collaboration agreement 05/10/22 Agilent reports expanded CE-IVD mark in Europe for companion diagnostic 04/05/22 Agilent expands CE-IVD marking in EU for PD-L1 IHC 28-8 pharmDx 02/28/22 Singular Genomics partners with Agilent for NGS Target Enrichment products 06/03/22 Cowen Agilent premium valuation remains warranted, says Cowen 06/02/22 KeyBanc Agilent price target lowered to $155 from $195 at KeyBanc 05/25/22 Baird Agilent price target raised to $161 from $155 at Baird 05/16/22 Citi Citi opens 'positive catalyst watch' on Agilent into earnings 04/28/22 Mizuho Alkermes price target raised to $36 from $35 at Mizuho 04/28/22 H.C. Wainwright Alkermes price target raised to $32 from $30 at H.C. Wainwright 04/27/22 Stifel Alkermes price target raised to $27 from $24 at Stifel 04/20/22 Goldman Sachs Alkermes initiated with a Buy at Goldman Sachs 05/12/22 Canaccord Biodesix price target lowered to $7 from $10 at Canaccord 04/20/22 Cowen Biodesix initiated with an Outperform at Cowen 04/18/22 BTIG Biodesix price target lowered to $10 from $17 at BTIG 03/15/22 Canaccord Biodesix price target lowered to $10 from $18 at Canaccord 05/19/22 Baird Baird says final LCD for test 'incrementally positive' for Castle Biosciences 05/10/22 Canaccord Castle Biosciences price target lowered to $65 from $80 at Canaccord 05/10/22 Baird Castle Biosciences price target lowered to $44 from $50 at Baird 05/09/22 BTIG Castle Biosciences transferred with a Buy at BTIG 05/23/22 SVB Securities AbbVie initiated with an Underperform at SVB Leerink 05/13/22 Piper Sandler Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler 05/06/22 Daiwa AbbVie downgraded to Neutral from Outperform at Daiwa 05/03/22 Morgan Stanley Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 03/17/22 JMP Securities Adicet Bio price target lowered to $21 from $30 at JMP Securities 03/08/22 Truist Adicet Bio initiated with a Buy at Truist 03/04/22 Jefferies Adicet Bio initiated with a Buy at Jefferies 03/02/22 Barclays Arcellx initiated with an Overweight at Barclays 03/01/22 SVB Securities Arcellx initiated with an Outperform at SVB Leerink 03/01/22 BofA Arcellx initiated with a Buy at BofA 03/01/22 BofA Arcellx initiated with a Buy at BofA 11/11/21 Roth Capital Roth says Adaptimmune synovial sarcoma trial hitting goal appears 'a certainty' 06/03/22 Oppenheimer Turning Point Therapeutics downgraded to Perform from Outperform at Oppenheimer 05/31/22 Evercore ISI Enanta upgraded to In Line from Underperform at Evercore ISI 05/25/22 Piper Sandler Piper Sandler says Ventyx Biosciences' VTX002 could produce superior efficacy 05/23/22 Piper Sandler Biohaven price target lowered to $149 from $170 at Piper Sandler 05/06/22 H.C. Wainwright Puma Biotechnology price target lowered to $12 from $14 at H.C. Wainwright 09/28/21 Fly Intel: Top five analyst upgrades 09/28/21 Citi Puma Biotechnology upgraded to Buy after 40% selloff at Citi 09/27/21 Citi Puma Biotechnology upgraded to Buy from Neutral at Citi 01/27/22 Canaccord Oncolytics price target lowered to $6 from $7 at Canaccord 06/02/22 Piper Sandler Invitae initiated with an Underweight at Piper Sandler 05/04/22 Raymond James Invitae price target lowered to $8.50 from $10.50 at Raymond James 02/28/22 Raymond James Invitae price target lowered to $15 from $36 at Raymond James 11/09/21 Wells Fargo Invitae price target lowered to $25 from $35 at Wells Fargo 05/13/22 Piper Sandler Point Biopharma price target lowered to $14 from $17 at Piper Sandler 05/13/22 Jefferies Roche downgraded to Hold from Buy at Jefferies 05/09/22 Wolfe Research Novartis downgraded to Peer Perform from Outperform at Wolfe Research 06/02/22 Piper Sandler NeoGenomics initiated with an Overweight at Piper Sandler 03/29/22 Cowen NeoGenomics price target lowered to $24 from $42 at Cowen 03/29/22 BTIG NeoGenomics price target lowered to $28 from $35 at BTIG 03/29/22 SVB Securities NeoGenomics price target lowered to $20 from $45 at SVB Leerink 05/27/22 BofA Molecular Templates downgraded to Underperform from Buy at BofA 05/13/22 Stifel Molecular Templates price target lowered to $9 from $11 at Stifel 03/30/22 Barclays Molecular Templates price target lowered to $4.50 from $8 at Barclays 04/28/22 Chardan VBL Therapeutics initiated with a Buy at Chardan 08/30/21 Roth Capital Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes 06/15/21 Roth Capital Roth does not see material change to VBL readout timelines 10/27/21 SVB Securities Seagen price target raised to $200 from $190 at SVB Leerink GLSI Greenwich LifeSciences 09/01/21 H.C. Wainwright Greenwich LifeSciences initiated with a Buy at H.C. Wainwright RTX Raytheon Technologies 04/27/22 Argus Raytheon Technologies price target raised to $112 from $100 at Argus 04/27/22 Cowen Raytheon Technologies price target raised to $120 from $115 at Cowen 04/08/22 RBC Capital Raytheon Technologies initiated with an Outperform at RBC Capital 03/29/22 Jefferies Northrop among biggest beneficiaries of DoD budget request, says Jefferies 04/08/22 Roth Capital Bicycle reported 'very strong' side-effect profile, says Roth Capital 04/08/22 Cantor Fitzgerald Bicycle Therapeutics' BT8009 abstract 'very positive,' says Cantor Fitzgerald 02/24/22 Piper Sandler Seagen's tisotumab vedotin shows 'modest signal of activity,' says Piper Sandler 02/16/22 JMP Securities Seagen price target lowered to $142 from $201 at JMP Securities 06/02/22 Piper Sandler Piper ups Repare Therapeutics target after 'great deal' with Roche 05/19/22 Credit Suisse Roche price target lowered to CHF 350 from CHF 370 at Credit Suisse 05/12/22 Morgan Stanley Roche price target lowered to CHF 370 from CHF 395 at Morgan Stanley 05/19/22 Piper Sandler Exelixis sold off on Cabometyx patent trial comments, says Piper Sandler 05/19/22 Truist Exelixis should be bought on dip caused by '776 patent worries, says Truist 05/12/22 Jefferies Exelixis could approach $26-$28 if it settles or wins MSN trial, says Jefferies 03/14/22 Piper Sandler Exelixis price target lowered to $30 from $34 at Piper Sandler 09/22/21 Fly Intel: Top five analyst downgrades 09/22/21 Goldman Sachs FibroGen downgraded to Sell from Neutral at Goldman Sachs 08/20/21 Raymond James FibroGen upgraded to Market Perform from Underperform at Raymond James 08/20/21 Raymond James FibroGen upgraded to Market Perform from Underperform at Raymond James 05/26/22 Barclays Cardinal Health downgraded to Equal Weight from Overweight at Barclays 05/18/22 Evercore ISI Evercore upgrades Cardinal Health to Outperform on undervalued Medical segment 05/18/22 Evercore ISI Cardinal Health upgraded to Outperform from In Line at Evercore ISI 04/12/22 Morgan Stanley McKesson price target raised to $370 from $292 at Morgan Stanley CBIO Catalyst Biosciences 05/23/22 Piper Sandler Piper Sandler remains bullish on Catalyst after sale of complement portfolio 03/31/22 Piper Sandler Piper says 'stick it out' with Catalyst Biosciences exploring options 11/12/21 JonesTrading Catalyst Biosciences downgraded to Hold from Buy at JonesTrading 11/12/21 Piper Sandler Catalyst Biosciences price target lowered to $4 from $16 at Piper Sandler 05/23/22 Piper Sandler Arvinas price target lowered to $76 from $116 at Piper Sandler 05/09/22 Wedbush Wedbush downgrades Arvinas to Neutral, cuts price target to $43 05/09/22 Wedbush Arvinas downgraded to Neutral from Outperform at Wedbush 05/06/22 Cantor Fitzgerald Arvinas assumed with an Overweight at Cantor Fitzgerald 11/23/21 SVB Securities Aura Biosciences initiated with an Outperform at SVB Leerink 11/23/21 BTIG Aura Biosciences initiated with a Buy at BTIG 11/23/21 Evercore ISI Evercore starts Aura Biosciences at Outperform with $35 price target 11/23/21 Cowen Aura Biosciences initiated with an Outperform at Cowen 05/17/22 VBL Therapeutics reports Q1 EPS (13c), consensus (11c) 03/23/22 VBL Therapeutics reports FY21 EPS (45c), consensus (41c) 04/28/22 Seagen sees FY22 total revenue $1.665B-$1.745B, consensus $1.78B 04/28/22 Seagen reports Q1 EPS (74c), consensus ($1.00) 02/10/22 Seagen sees FY22 total revenue $1.67B-$1.75B, consensus $2.16B 02/09/22 Seagen reports Q4 EPS (95c), consensus (83c) RTX Raytheon Technologies 04/26/22 Raytheon Technologies backs FY22 adjusted EPS view $4.60-$4.80, consensus $4.79 04/26/22 Raytheon Technologies reports Q1 adjusted EPS $1.15, consensus $1.01 04/25/22 Notable companies reporting before tomorrow's open 04/25/22 Roche reports Q1 group sales CHF 16.445B vs. CHF 14.93B last year 02/03/22 Roche sees FY22 core earnings growing in low- to mid-single digit range 02/03/22 Roche reports 2021 core EPS CHF 19.81 vs CHF 19.16 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open 05/05/22 Puma Biotechnology reports Q1 EPS (1c), consensus (17c) 03/03/22 Puma Biotechnology reports Q4 EPS 21c, consensus (9c) 05/05/22 Oncolytics reports Q1 EPS 12c, consensus (11c) 03/03/22 Oncolytics reports Q4 EPS (14c), consensus (10c) 05/03/22 Invitae reports Q1 non-GAAP EPS 78c, consensus (76c) 02/24/22 Invitae sees 2022 revenue $640M, consensus $638.69M 02/24/22 Invitae reports Q4 non-GAAP EPS (81c), consensus (73c) 04/26/22 Novartis sees 2022 core operating income to grow mid single digit 04/26/22 Novartis reports Q1 core EPS $1.46, consensus $1.46 02/02/22 Novartis sees 2022 sales, core operating income up mid single digit 02/02/22 Novartis reports Q4 core EPS $1.40 vs. $1.34 last year 04/27/22 NeoGenomics reports Q1 adjusted EPS (20c), consensus (23c) 04/26/22 Notable companies reporting before tomorrow's open 03/28/22 NeoGenomics now sees Q1 revenue below $118M-$120M range, consensus $119.16M 05/13/22 Molecular Templates reports Q1 EPS (38c), consensus (47c) 03/28/22 Molecular Templates reports Q4 EPS (18c), consensus (40c) 05/09/22 FibroGen reports Q1 EPS (68c), consensus (83c) 02/28/22 FibroGen reports Q EPS ($1.45), consensus (66c) 05/10/22 Exelixis sees FY22 revenue $1.525B-$1.625B, consensus $1.64B 05/10/22 Exelixis reports Q1 adjusted EPS 26c, consensus 14c 02/17/22 Exelixis reports Q4 adjusted EPS 35c, consensus 6c 01/09/22 Exelixis sees preliminary Q4 net product revenue $300M 05/09/22 Castle Biosciences raises FY22 revenue view to $118M-$123M from $115M-$120M 05/09/22 Castle Biosciences reports Q1 EPS (97c), consensus (71c) 02/28/22 Castle Biosciences sees FY22 revenue $115M-$120M, consensus $113.54M 02/28/22 Castle Biosciences reports Q4 EPS (25c), consensus (47c) CBIO Catalyst Biosciences 05/09/22 Catalyst Biosciences reports Q1 EPS (46c), consensus (44c) 03/31/22 Catalyst Biosciences reports Q4 EPS (65c), consensus (59c) 05/05/22 Cardinal Health narrows FY21 EPS view to $5.15-$5.25 from $5.15-$5.50 05/05/22 Cardinal Health reports Q3 EPS $1.45, consensus $1.52 02/03/22 Cardinal Health cuts FY22 EPS view to $5.15-$5.50 from $5.60-$5.90 02/03/22 Cardinal Health reports Q2 EPS $1.27, consensus $1.23 05/11/22 Biodesix still sees 2022 revenue $37.5M-$39.5M, consensus $38.41M 05/11/22 Biodesix reports Q1 EPS (50c), consensus (40c) 03/14/22 Biodesix sees FY22 revenue $37.5M-$39.5M, consensus $35.5M 03/14/22 Biodesix reports Q4 EPS (49c), consensus (49c) 03/23/22 Aura Biosciences reports FY21 EPS ($8.95), consensus ($4.41) 05/05/22 Arvinas reports Q1 EPS ($1.20), consensus (89c) 02/28/22 Arvinas reports Q4 EPS ($1.00), consensus (79c) 04/27/22 Alkermes reiterates 2022 financial expectations given in February 04/27/22 Alkermes reports Q1 EPS 12c, consensus 1c 02/16/22 Alkermes updates long-term profitability targets for Invega royalty removal 02/16/22 Alkermes sees FY22 adjusted EPS (18c)-0c, consensus 35c 05/09/22 Adaptimmune reports Q1 EPS (5c), consensus (22c) 03/14/22 Adaptimmune reports Q4 EPS (4c), consensus 14c 05/12/22 Arcellx reports Q1 EPS ($1.56), consensus (64c) 03/24/22 Arcellx reports Q4 EPS ($39.85) vs. ($28.27) a year ago 05/12/22 Adicet Bio reports Q1 EPS (12c), consensus (18c) 03/15/22 Adicet Bio reports Q4 EPS (47c), consensus (42c) 04/29/22 AbbVie sees FY22 revenue $59.4B, consensus $60.22B 04/29/22 AbbVie sees Q2 adjusted EPS $3.38-$3.42, consensus $3.50 04/29/22 AbbVie cuts FY22 adjusted EPS view to $13.92-$14.12 from $14.00-$14.20 04/29/22 AbbVie reports Q1 adjusted EPS $3.16, consensus $3.14 05/24/22 Agilent raises FY22 EPS view to $4.86-$4.93, consensus $4.60 05/24/22 Agilent sees Q3 EPS $1.20-$1.22, consensus $1.12 05/24/22 Agilent reports Q2 EPS $1.13, consensus $1.06 02/22/22 Agilent raises FY22 EPS view to $4.80-$4.90, consensus $4.27
Recommendations
Cowen analyst Dan Brennan…
Cowen analyst Dan Brennan believes the Agilent fundamentals are solid and the valuation premium is warranted and risks are manageable with the sector facing less pressure from recession versus. the 2008-2009 period. Brennan reiterated his Outperform rating and $159 price target on Agilent shares.
Show Hide Related Items >> <<
05/27/22 Agilent, APC announce liquid chromatography collaboration agreement 05/10/22 Agilent reports expanded CE-IVD mark in Europe for companion diagnostic 04/05/22 Agilent expands CE-IVD marking in EU for PD-L1 IHC 28-8 pharmDx 02/28/22 Singular Genomics partners with Agilent for NGS Target Enrichment products 06/02/22 KeyBanc Agilent price target lowered to $155 from $195 at KeyBanc 05/25/22 Baird Agilent price target raised to $161 from $155 at Baird 05/16/22 Citi Citi opens 'positive catalyst watch' on Agilent into earnings 04/25/22 Wells Fargo Agilent downgraded to Equal Weight from Overweight at Wells Fargo 05/24/22 Agilent raises FY22 EPS view to $4.86-$4.93, consensus $4.60 05/24/22 Agilent sees Q3 EPS $1.20-$1.22, consensus $1.12 05/24/22 Agilent reports Q2 EPS $1.13, consensus $1.06 02/22/22 Agilent raises FY22 EPS view to $4.80-$4.90, consensus $4.27 05/24/22 Fly Intel: After-Hours Movers 03/28/22 Fly Insider: GameStop, Agilent among this week's notable insider trades 05/24/22 Agilent options imply 4.7% move in share price post-earnings
Conference/Events
Conference call with CEO…
Conference call with CEO McMullen to be held on June 2 at 1 pm hosted by JPMorgan. Webcast Link
Show Hide Related Items >> <<
05/27/22 Agilent, APC announce liquid chromatography collaboration agreement 05/10/22 Agilent reports expanded CE-IVD mark in Europe for companion diagnostic 04/05/22 Agilent expands CE-IVD marking in EU for PD-L1 IHC 28-8 pharmDx 02/28/22 Singular Genomics partners with Agilent for NGS Target Enrichment products 06/02/22 KeyBanc Agilent price target lowered to $155 from $195 at KeyBanc 05/25/22 Baird Agilent price target raised to $161 from $155 at Baird 05/16/22 Citi Citi opens 'positive catalyst watch' on Agilent into earnings 04/25/22 Wells Fargo Agilent downgraded to Equal Weight from Overweight at Wells Fargo 05/24/22 Agilent raises FY22 EPS view to $4.86-$4.93, consensus $4.60 05/24/22 Agilent sees Q3 EPS $1.20-$1.22, consensus $1.12 05/24/22 Agilent reports Q2 EPS $1.13, consensus $1.06 02/22/22 Agilent raises FY22 EPS view to $4.80-$4.90, consensus $4.27 05/24/22 Fly Intel: After-Hours Movers 03/28/22 Fly Insider: GameStop, Agilent among this week's notable insider trades 05/24/22 Agilent options imply 4.7% move in share price post-earnings
Recommendations
KeyBanc analyst Paul…
KeyBanc analyst Paul Knight lowered the firm's price target on Agilent to $155 from $195 to reflect the contraction in peer-group multiples, while keeping an Overweight rating on the shares. Shanghai, the most significant market in China for Life Tool companies, has moved to reopen the metro area this week. The news comes as Agilent's valuation has retraced close to its five-year median EV/EBITDA, the analyst notes. The company, very close to the China market with a long operating history and the majority of its 33% Asian sales tied to the country, had previously indicated a back-half fiscal 2022 recovery. Knight sees higher visibility to his estimates and an attractive valuation for the shares.
Show Hide Related Items >> <<
05/27/22 Agilent, APC announce liquid chromatography collaboration agreement 05/10/22 Agilent reports expanded CE-IVD mark in Europe for companion diagnostic 04/05/22 Agilent expands CE-IVD marking in EU for PD-L1 IHC 28-8 pharmDx 02/28/22 Singular Genomics partners with Agilent for NGS Target Enrichment products 05/25/22 Baird Agilent price target raised to $161 from $155 at Baird 05/16/22 Citi Citi opens 'positive catalyst watch' on Agilent into earnings 04/25/22 Wells Fargo Agilent downgraded to Equal Weight from Overweight at Wells Fargo 04/19/22 Truist Moog Inc downgraded to Hold from Buy at Truist 05/24/22 Agilent raises FY22 EPS view to $4.86-$4.93, consensus $4.60 05/24/22 Agilent sees Q3 EPS $1.20-$1.22, consensus $1.12 05/24/22 Agilent reports Q2 EPS $1.13, consensus $1.06 02/22/22 Agilent raises FY22 EPS view to $4.80-$4.90, consensus $4.27 05/24/22 Fly Intel: After-Hours Movers 03/28/22 Fly Insider: GameStop, Agilent among this week's notable insider trades 05/24/22 Agilent options imply 4.7% move in share price post-earnings
Over a month ago
Hot Stocks
Agilent announced a…
Agilent announced a collaboration agreement with APC in which the companies commit to working towards combining their technologies to provide unique workflows to customers that support automated process analysis via liquid chromatography, or LC. Agilent has selected to partner with APC, a provider of small molecule and large molecule process design and process development solutions. Both APC and Agilent pursue similar goals, which are focused on helping customers in the biopharmaceutical and pharmaceutical industry to improve the human condition and to delivering life-changing drugs to market faster and more efficiently. The collaboration between the companies leverages their complementary strengths to develop specific workflows, which bridge the gap between the analytical and process solutions.
Show Hide Related Items >> <<
05/10/22 Agilent reports expanded CE-IVD mark in Europe for companion diagnostic 04/05/22 Agilent expands CE-IVD marking in EU for PD-L1 IHC 28-8 pharmDx 02/28/22 Singular Genomics partners with Agilent for NGS Target Enrichment products 02/24/22 Agilent and UVM establish Agilent Laboratory for Chemical Analysis 05/25/22 Baird Agilent price target raised to $161 from $155 at Baird 05/16/22 Citi Citi opens 'positive catalyst watch' on Agilent into earnings 04/25/22 Wells Fargo Agilent downgraded to Equal Weight from Overweight at Wells Fargo 04/19/22 Truist Moog Inc downgraded to Hold from Buy at Truist 05/24/22 Agilent raises FY22 EPS view to $4.86-$4.93, consensus $4.60 05/24/22 Agilent sees Q3 EPS $1.20-$1.22, consensus $1.12 05/24/22 Agilent reports Q2 EPS $1.13, consensus $1.06 02/22/22 Agilent raises FY22 EPS view to $4.80-$4.90, consensus $4.27 05/24/22 Fly Intel: After-Hours Movers 03/28/22 Fly Insider: GameStop, Agilent among this week's notable insider trades 05/24/22 Agilent options imply 4.7% move in share price post-earnings
Recommendations
Baird analyst Catherine…
Baird analyst Catherine Ramsey Schulte raised the firm's price target on Agilent to $161 from $155 and keeps an Outperform rating on the shares. The analyst said management remains bullish on the outlook in China, as well as its portfolio positioning/mix in a potential broader recessionary scenario. She continues to like Agilent's organic setup here, with the potential for incremental capital deployment to drive upside.
Show Hide Related Items >> <<
05/10/22 Agilent reports expanded CE-IVD mark in Europe for companion diagnostic 04/05/22 Agilent expands CE-IVD marking in EU for PD-L1 IHC 28-8 pharmDx 02/28/22 Singular Genomics partners with Agilent for NGS Target Enrichment products 02/24/22 Agilent and UVM establish Agilent Laboratory for Chemical Analysis 05/16/22 Citi Citi opens 'positive catalyst watch' on Agilent into earnings 04/25/22 Wells Fargo Agilent downgraded to Equal Weight from Overweight at Wells Fargo 04/19/22 Truist Moog Inc downgraded to Hold from Buy at Truist 02/23/22 Wells Fargo Agilent price target lowered to $160 from $180 at Wells Fargo 05/24/22 Agilent raises FY22 EPS view to $4.86-$4.93, consensus $4.60 05/24/22 Agilent sees Q3 EPS $1.20-$1.22, consensus $1.12 05/24/22 Agilent reports Q2 EPS $1.13, consensus $1.06 02/22/22 Agilent raises FY22 EPS view to $4.80-$4.90, consensus $4.27 05/24/22 Fly Intel: After-Hours Movers 03/28/22 Fly Insider: GameStop, Agilent among this week's notable insider trades 05/24/22 Agilent options imply 4.7% move in share price post-earnings
On The Fly
Check out this evening's…
Show Hide Related Items >> <<
05/24/22 Wendy's board to 'carefully review any proposal submitted by Trian Partners' 05/24/22 Wendy's up 15% to $18.70 following Trian 13D/A filing on potential transaction 05/24/22 Wendy's shareholder Trian to explore potential transaction 05/14/22 Trian exits Comcast position, increases stake in Invesco 04/11/22 21Vianet trading resumes 04/11/22 VNET Group receives $1.3333 per ordinary share buyout proposal 04/11/22 21Vianet trading halted, news pending 01/28/22 VNET Group announces $250M investment from Blackstone 05/24/22 Urban Outfitters says 21.5M shares of common stock remain available for buyback 04/13/22 Creatd's Dune wellness drink to be sold at Urban Outfitters 03/01/22 Urban Outfitters CEO says Q1 SSS to rise mid-teens 01/11/22 Urban Outfitters reports net sales for two months ended Dec. 31 up 14.6% 05/24/22 Toll Brothers CEO 'very pleased' with Q2 performance 05/24/22 Toll Brothers sees FY22 deliveries 11,000-11,500 units 05/24/22 Toll Brothers sees Q3 deliveries 2,750 units 05/24/22 Toll Brothers announces $900M share repurchase plan 05/16/22 Jana Partners exits Macy's, cuts LabCorp in Q1 05/16/22 Tepper's Appaloosa buys two casinos in Q1, exits T-Mobile and GM 04/07/22 Macy's CFO believes consumers will spend, says 'demand is out there' $16.72 / -3.515 (-17.37%)
05/06/22 Lyft says Shared rides returning to more markets this May 05/03/22 Lyft drops 26% to $22.67 after Q2 revenue guidance misses estimates 04/29/22 Lyft identifies error in accounting for Q1 financial statements 04/19/22 Lyft makes masks optional while riding or driving KDNY Chinook Therapeutics 05/20/22 Chinook announces two oral presentations on atrasentan clinical program 04/12/22 Chinook Therapeutics announces initiation of Phase 1 trial of CHK-336 04/05/22 Chinook, IgA Nephropathy Foundation, Komodo Health announce collaboration 03/21/22 Chinook Therapeutics announces appointment of Krishnan to board of directors 05/24/22 Nordstrom up 12% after Q1 report, Macy's up 4% in sympathy 05/24/22 Nordstrom jumps 12% to $23.07 after FY22 guidance tops estimates 05/24/22 Nordstrom reports Q1 GMV up 19.6% 05/24/22 Nordstrom board authorizes new $500M share repurchase program $358.78 / -12.425 (-3.35%)
05/24/22 Intuit up 2.8% to $369.05 after Q3 earnings beat and raised FY22 guidance 05/16/22 Third Point lowers stakes in Amazon, Intuit, exits Alphabet position 05/04/22 Intuit to record $141M one-time charge for settlement 05/04/22 California AG announces $141M nationwide settlement with Intuit 02/28/22 InterDigital, Zip Code Wilmington expand partnership 01/10/22 InterDigital, Sony Corporation of America extend pact and renew patent license $235.40 / -13.25 (-5.33%)
05/12/22 Dillard's still sees 2022 CapEx $150M up from $104M in 2021 02/24/22 Dillard's announces $500M share repurchase program 02/22/22 Dillard's sees 2022 CapEx $150M from $104M in 2021 05/24/22 Caleres jumps 8.7% to $22.75 after Q1 earnings beat, FY22 guidance raise 05/11/22 Ryka releases XpectFit sneaker collection designed for pregnancy 03/15/22 Caleres board authorizes incremental 7M share buyback 05/24/22 AdaptHealth institutional holder Skyknight Capital buys $3.62M in common stock 05/10/22 AdaptHealth board authorizes $200M share repurchase program 05/10/22 Agilent reports expanded CE-IVD mark in Europe for companion diagnostic 04/05/22 Agilent expands CE-IVD marking in EU for PD-L1 IHC 28-8 pharmDx 02/28/22 Singular Genomics partners with Agilent for NGS Target Enrichment products 02/24/22 Agilent and UVM establish Agilent Laboratory for Chemical Analysis 01/11/22 Loop Capital Loop Capital upgrades Steven Madden to Buy after positive news from peers 11/19/21 Loop Capital Caleres price target raised to $40 from $35 at Loop Capital 09/07/21 Loop Capital Caleres price target raised to $35 from $30 at Loop Capital 06/01/21 Loop Capital Caleres price target raised to $30 from $25 at Loop Capital 05/16/22 JPMorgan Nordstrom price target lowered to $22 from $24 at JPMorgan 03/02/22 BMO Capital Nordstrom price target raised to $30 from $23 at BMO Capital 03/02/22 Deutsche Bank Nordstrom price target raised to $31 from $22 at Deutsche Bank 03/02/22 Citi Nordstrom price target raised to $27 from $25 at Citi $235.40 / -13.25 (-5.33%)
05/16/22 JPMorgan Dillard's price target raised to $185 from $160 at JPMorgan 11/30/21 UBS Dillard's initiated with a Sell at UBS 05/16/22 JPMorgan Macy's price target lowered to $30 from $33 at JPMorgan 05/11/22 OTR Global Macy's view downgraded to Mixed from Positive at OTR Global 02/24/22 Citi Citi upgrades Macy's to Neutral with challenges priced in 02/24/22 Citi Macy's upgraded to Neutral from Sell at Citi 05/16/22 Credit Suisse VNET Group price target lowered to $8.20 from $10.80 at Credit Suisse 04/22/22 Jefferies Selloff in China IDC stocks 'significantly overdone,' says Jefferies 11/22/21 HSBC VNET Group upgraded to Buy from Hold at HSBC 11/19/21 Jefferies Jefferies keeps Buy rating on VNET Group, says market concerns 'misplaced' 04/13/22 JPMorgan Toll Brothers price target lowered to $51 from $58 at JPMorgan 04/05/22 Credit Suisse Toll Brothers initiated with an Outperform at Credit Suisse 03/31/22 Barclays Toll Brothers price target lowered to $47 from $61 at Barclays 03/25/22 Citi Toll Brothers price target lowered to $52 from $62 at Citi 05/23/22 Citi Urban Outfitters price target lowered to $30 from $42 at Citi 05/17/22 B. Riley Urban Outfitters price target lowered to $39 from $44 at B. Riley 05/16/22 JPMorgan Urban Outfitters price target lowered to $26 from $32 at JPMorgan 04/05/22 Wells Fargo Urban Outfitters price target lowered to $28 from $34 at Wells Fargo $358.78 / -12.425 (-3.35%)
05/20/22 Barclays Intuit price target lowered to $480 from $585 at Barclays 05/02/22 BMO Capital Intuit price target lowered to $550 from $600 at BMO Capital 04/25/22 Wells Fargo Intuit price target lowered to $635 from $725 at Wells Fargo 03/21/22 BMO Capital Indicators suggest 'slow forming tax season' for Intuit, says BMO Capital 05/16/22 Citi Citi opens 'positive catalyst watch' on Agilent into earnings 04/25/22 Wells Fargo Agilent downgraded to Equal Weight from Overweight at Wells Fargo 04/19/22 Truist Moog Inc downgraded to Hold from Buy at Truist 02/23/22 Wells Fargo Agilent price target lowered to $160 from $180 at Wells Fargo 05/12/22 Truist Wendy's price target lowered to $27 from $29 at Truist 05/12/22 Wedbush Wendy's price target lowered to $23 from $28.50 at Wedbush 05/12/22 Deutsche Bank Wendy's price target lowered to $20 from $26 at Deutsche Bank 05/12/22 Barclays Wendy's price target lowered to $25 from $28 at Barclays 05/12/22 Canaccord AdaptHealth price target lowered to $26 from $29 at Canaccord 05/11/22 Deutsche Bank AdaptHealth price target lowered to $22 from $28 at Deutsche Bank 03/08/22 RBC Capital AdaptHealth price target lowered to $26 from $31 at RBC Capital 02/25/22 Canaccord AdaptHealth price target lowered to $29 from $44 at Canaccord $16.72 / -3.515 (-17.37%)
05/23/22 Bernstein Lyft assumed with a Market Perform at Bernstein 05/16/22 Argus Lyft price target lowered to $41 from $72 at Argus 05/05/22 DA Davidson Lyft price target lowered to $27 from $60 at DA Davidson 05/05/22 MKM Partners Uber price target lowered to $41 from $65 at MKM Partners 08/03/21 Roth Capital Court ruling sets tone for unlicensed Chinese OEMs in Europe, says Roth Capital KDNY Chinook Therapeutics 02/01/22 H.C. Wainwright H.C. Wainwright sees no negative read-through from Chinook CMO departure 05/11/22 Wendy's backs FY22 adjusted EPS view 82c-86c, consensus 87c 05/11/22 Wendy's reports Q1 adjusted EPS 17c, consensus 18c 05/10/22 Notable companies reporting before tomorrow's open 05/24/22 VNET Group reports Q1 adjusted EBITDA up 21.9% y/y to $79.8M 03/30/22 VNET Group sees FY22 revenue RMB 7.45B-RMB 7.75B 03/30/22 VNET Group reports Q4 EPS (24c), consensus (22c) 05/24/22 Urban Outfitters reports Q1 EPS 33c, consensus 42c 03/01/22 Urban Outfitters reports Q4 EPS 41c, consensus 50c 02/10/22 Urban Outfitters reports Q4 revenue $1.33B, consensus $1.33B 05/24/22 Toll Brothers reports Q2 EPS $1.85, consensus $1.54 02/22/22 Toll Brothers reports Q1 EPS $1.24, consensus $1.15 02/22/22 Notable companies reporting after market close 02/22/22 Macy's sees Q1 adjusted EPS 77c-85c, consensus 46c 02/22/22 Macy's sees FY22 adjusted EBITDA as percentage of sales 11%-11.5% 02/22/22 Macy's sees FY22 adjusted EPS $4.13-$4.52, consensus $4.06 02/22/22 Macy's reports Q4 adjusted EPS $2.45, consensus $1.99 $16.72 / -3.515 (-17.37%)
05/03/22 Lyft sees Q2 revenue $950M-$1B, consensus $1.02B 05/03/22 Lyft reports Q1 Active Riders 17,804, up 31.9% 05/03/22 Lyft reports Q1 EPS (57c), consensus (7c) 05/03/22 Lyft reports Q1 EPS (57c), consensus (7c) KDNY Chinook Therapeutics 05/12/22 Chinook Therapeutics reports Q1 EPS (54c), consensus (67c) 03/17/22 Chinook Therapeutics reports Q4 EPS 14c, consensus (68c) 05/24/22 Nordstrom raises FY22 adjusted EPS view to $3.20-$3.50 from $3.15-$3.50 05/24/22 Nordstrom reports Q1 EPS (6c), consensus (5c) 05/24/22 Notable companies reporting after market close 03/01/22 Nordstrom sees FY22 EPS $3.15-$3.50, consensus $2.01 $358.78 / -12.425 (-3.35%)
05/24/22 Intuit sees Q4 EPS 94c-$1.00, consensus 96c 05/24/22 Intuit raises FY22 EPS view to $11.68-$11.74, consensus $11.64 05/24/22 Intuit reports Q3 EPS $7.65, consensus $7.58 05/05/22 InterDigital sees Q2 revenue $114M-$120M, two est. $100M 05/05/22 InterDigital reports Q1 EPS 58c vs. 18c last year 02/17/22 InterDigital sees Q1 revenue $95M-$100M, two est. $99.79M 02/17/22 InterDigital reports Q4 EPS 70c, two est. 34c $235.40 / -13.25 (-5.33%)
05/12/22 Dillard's reports Q1 EPS $13.68, consensus $6.74 02/22/22 Dillard's reports Q4 EPS $16.61, consensus $11.40 05/24/22 Caleres sees Q2 'in-line with Q1 levels' 05/24/22 Caleres raises FY22 EPS view to $4.20-$4.40 from $3.75-$4.00, consensus $3.92 05/24/22 Caleres reports Q1 adjusted EPS $1.32, consensus 83c 03/15/22 Caleres sees FY22 EPS $3.75-$4.00, consensus $4.03 05/10/22 AdaptHealth sees 2022 revenue $2.84B-$3.04B, consensus $2.92B 05/10/22 AdaptHealth reports Q1 EPS 8c, consensus 18c 02/24/22 AdaptHealth raises FY22 revenue view to $2.825B-$3.025B from $2.7B-$2.9B 02/24/22 AdaptHealth reports Q4 EPS 15c, consensus 34c 05/24/22 Agilent raises FY22 EPS view to $4.86-$4.93, consensus $4.60 05/24/22 Agilent sees Q3 EPS $1.20-$1.22, consensus $1.12 05/24/22 Agilent reports Q2 EPS $1.13, consensus $1.06 02/22/22 Agilent raises FY22 EPS view to $4.80-$4.90, consensus $4.27
Earnings
Prior guidance was…
Prior guidance was $4.80-$4.90. Backs FY22 revenue view of $6.67B-$6.73B, consensus $6.36B.
Show Hide Related Items >> <<
05/10/22 Agilent reports expanded CE-IVD mark in Europe for companion diagnostic 04/05/22 Agilent expands CE-IVD marking in EU for PD-L1 IHC 28-8 pharmDx 02/28/22 Singular Genomics partners with Agilent for NGS Target Enrichment products 02/24/22 Agilent and UVM establish Agilent Laboratory for Chemical Analysis 05/16/22 Citi Citi opens 'positive catalyst watch' on Agilent into earnings 04/25/22 Wells Fargo Agilent downgraded to Equal Weight from Overweight at Wells Fargo 04/19/22 Truist Moog Inc downgraded to Hold from Buy at Truist 02/23/22 Wells Fargo Agilent price target lowered to $160 from $180 at Wells Fargo 05/24/22 Agilent sees Q3 EPS $1.20-$1.22, consensus $1.12 05/24/22 Agilent reports Q2 EPS $1.13, consensus $1.06 02/22/22 Agilent raises FY22 EPS view to $4.80-$4.90, consensus $4.27 02/22/22 Agilent sees Q2 EPS $1.10-$1.12, consensus 99c 03/28/22 Fly Insider: GameStop, Agilent among this week's notable insider trades 05/24/22 Agilent options imply 4.7% move in share price post-earnings
